EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

By Spicer James  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396

Spandidos Publications

Access to resources Recommend Favorite

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

By Kao Hsiang-Fong   Lin Chia-Chi   Yang James Chih-Hsin  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 991-1003

Future Medicine

Access to resources Recommend Favorite

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

By Califano Raffaele  

Targeted Oncology, Vol. 3, Iss. 3, 2008-07 ,pp. : 173-186

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite